Abstract: Described herein are compositions comprising, and methods for using a composition comprising, Staphylococcal Exfoliative Toxin A (ETA) in an amount and duration sufficient to decrease the Stratum Corneum in a region of a subjects skin.

Abstract: Methods and compositions for treatment of pain, mood, or for the treatment of opiate withdrawal symptoms with the modulation of systemic beta-endorphin levels by the topical administration of cAMP elevating agents and/or dermal exposure to ultraviolet (UV) irradiation.

Abstract: Provided herein are methods that can be used to produce a local immune response in cancer tissue and/or enhance effectiveness of cancer treatment in a subject through application of one or more combinations of: an ablative fractional laser procedure, a checkpoint inhibitor, and an endosomal TLR agonist (e.g., a TLR3, TLR7, TLR8 or TLR9 agonist).

Abstract: Embodiments described here are combinatorial compositions and methods using these compositions for treating melanomas having activated mutations. The compositions comprises combinations of inhibitors of a MAPK pathway, ERK inhibitors, EGFR inhibitors, oxidative phosphorylation (OXPHOS) inhibitors, inhibitors of B-Raf, mitochondrial inhibitors, c-KIT inhibitors, MEK inhibitors and tigecycline or a derivative thereof.

Abstract: A system for visualizing melanin present in tissue can include an imaging system to record a signal based on a presence of melanin in tissue and a display device to display an image based on the signal. A first laser source can emit a Stokes pulse train and a second laser source can emit a pump pulse train. Both the first laser source and the second laser source comprise a tunable center wavelength or frequency. An energy difference between a frequency of the Stokes pulse train and a frequency of the pump pulse train is from 1750 cm?1 to 2250 cm?1. The Stokes and the pump pulse train overlap in space and time. A scanning mechanism focuses the combined Stokes pulse train and pump pulse train within the tissue and scans across the tissue. A detector detects the signal based on a presence of melanin within the tissue.

Abstract: Provided herein are compounds of the formula (IV): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.

Abstract: Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.

Abstract: Methods and compositions for treatment of pain, mood, or for the treatment of opiate withdrawal symptoms with the modulation of systemic beta-endorphin levels by the topical administration of cAMP elevating agents and/or dermal exposure to ultraviolet (UV) irradiation.

Abstract: Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.

Abstract: Embodiments described here are combinatorial compositions and methods using these compositions for treating melanomas having activated mutations. The compositions comprises combinations of inhibitors of a MAPK pathway, ERK inhibitors, EGFR inhibitors, oxidative phosphorylation (OXPHOS) inhibitors, inhibitors of B-Raf, mitochondrial inhibitors, c-KIT inhibitors, MEK inhibitors and tigecycline or a derivative thereof.

Abstract: Embodiments disclosed are transgenic mice having mutations in a MC1R and a BRAF gene. Such transgenic mice have high incidences of invasive melanomas. These transgenic mice are useful animal systems and tools for screening test candidates for the treatment of melanoma involving MC1R and BRAF mutations.

Abstract: This invention relates to a method for regulating skin pigmentation of a subject, comprising the step of administering the agent for inhibiting the expression or activation of Microphthalmia Transcription Factor (MITF) to the subject who is in need of regulation of skin pigmentation.

Abstract: The invention provides seed and plants of sweet corn hybrid SEY6RH1263 and the parent lines thereof. The invention thus relates to the plants, seeds and tissue cultures of sweet corn hybrid SEY6RH1263 and the parent lines thereof, and to methods for producing a sweet corn plant produced by crossing such plants with themselves or with another sweet corn plant, such as a plant of another genotype. The invention further relates to seeds and plants produced by such crossing. The invention further relates to parts of such plants, including the parts of such plants.

Abstract: The invention provides seed and plants of sweet corn hybrid SEY6RH1264 and the parent lines thereof. The invention thus relates to the plants, seeds and tissue cultures of sweet corn hybrid SEY6RH1264 and the parent lines thereof, and to methods for producing a sweet corn plant produced by crossing such plants with themselves or with another sweet corn plant, such as a plant of another genotype. The invention further relates to seeds and plants produced by such crossing. The invention further relates to parts of such plants, including the parts of such plants.

Abstract: The invention provides seed and plants of sweet corn hybrid SEY6RH1264 and the parent lines thereof. The invention thus relates to the plants, seeds and tissue cultures of sweet corn hybrid SEY6RH1264 and the parent lines thereof, and to methods for producing a sweet corn plant produced by crossing such plants with themselves or with another sweet corn plant, such as a plant of another genotype. The invention further relates to seeds and plants produced by such crossing. The invention further relates to parts of such plants, including the parts of such plants.

Abstract: The invention provides seed and plants of sweet corn hybrid SEY6RH1263 and the parent lines thereof. The invention thus relates to the plants, seeds and tissue cultures of sweet corn hybrid SEY6RH1263 and the parent lines thereof, and to methods for producing a sweet corn plant produced by crossing such plants with themselves or with another sweet corn plant, such as a plant of another genotype. The invention further relates to seeds and plants produced by such crossing. The invention further relates to parts of such plants, including the parts of such plants.

Abstract: Systemic beta-endorphin can be elevated in response to cutaneous irradiation, including ultraviolet and ionizing radiation. Increases in systemic beta-endorphin levels associated with cutaneous irradiation can be modulated with opiate receptor antagonists, particularly compounds that antagonize opioid receptor binding by beta endorphin.

Abstract: Microphthalmia (Mi) while present in melanocytes, a cells and osteoclast, is not normally present in other cells. We have found that Mi is present in the nucleus of melanoma cells. Melanoma can be diagnosed by contacting a malignant cell with a probe for Mi. If the probe identifies Mi in the nucleus of the cell, the cell is a melanoma.

Abstract: Microphthalmia (Mi) while present in melanocytes, a cells and osteoclast, is not normally present in other cells. We have found that Mi is present in the nucleus of melanoma cells. Melanoma can be diagnosed by contacting a malignant cell with a probe for Mi. If the probe identities Mi in the nucleus of the cell, the cell is a melanoma.

Abstract: Methods for treating melanoma and other MITF-related disorders by administering a compound that causes an increase in HIF-1 level or activity (e.g., by increasing the level of HIF-1I in a cell) within cells. Such methods include administration of a compound that is a hydroxylase inhibitor, e.g., a prolyl hydroxylase inhibitor that reduces hydroxylation of HIF-1I thereby causing an increase in HIF-1I in the cell. Such treatment can lead to a decrease in MITF activity or expression.